Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Collaborative Group, RECOVERY; Horby, Peter; Mafham, Marion; Peto, Leon; Campbell, Mark; Pessoa-Amorim, Guilherme; Spata, Enti; Staplin, Natalie; Emberson, Jonathan; Prudon, Benjamin; Hine, Paul; Brown, Thomas; Green, Christopher; Sarkar, Rahuldeb; Desai, Purav; Yates, Bryan; Bewick, Tom; Tiberi, Simon; Felton, Tim; Kenneth Baillie, J.; H Buch, Maya; C. Chappell, Lucy; Day, Jeremy; N. Faust, Saul; Jaki, Thomas; Jeffery, Katie; Juszczak, Edmund; Shen Lim, Wei; Montgomery, Alan; Mumford, Andrew; Rowan, Kathy; Thwaites, Guy; M. Weinreich, David; Haynes, Richard; Landray, Martin

doi:10.1101/2021.06.15.21258542

Public

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Published in medRxiv • Jun 16, 2021

Authors:

RECOVERY Collaborative Group

Peter Horby

Marion Mafham

Abstract

SUMMARY Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of REGEN-COV in patients admitted to hospital with COVID-...

Subject

Medicine

Population

Randomized controlled trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!